Glucose-lowering treatments and COVID-19 mortality in T2DM.

Hadjadj, Samy; Wargny, Matthieu

Hadjadj, Samy; Wargny, Matthieu.

Hadjadj S; l'institut du thorax, CNRS, INSERM, CHU Nantes, Université de Nantes, Nantes, France. samy.hadjadj@univ-nantes.fr.
Wargny M; Clinique des données, INSERM CIC 1413, CHU Nantes, Nantes, France.

Nat Rev Endocrinol ; 17(7): 387-388, 2021 07.

Article in English | MEDLINE | ID: covidwho-1226428

Subject(s)

COVID-19; Diabetes Mellitus, Type 2; Blood Glucose; Diabetes Mellitus, Type 2/drug therapy; England; Glucose; Humans; Hypoglycemic Agents/therapeutic use; Prescriptions; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / COVID-19 Limits: Humans Country/Region as subject: Europa Language: English Journal: Nat Rev Endocrinol Journal subject: Endocrinology Year: 2021 Document Type: Article Affiliation country: S41574-021-00509-x

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google